Director Abbas Hussain resigns from Teva board effective July 6, 2021

TEVA PHARMACEUTICAL INDUSTRIES LTD

Abbas Hussain resigned from Teva's Board effective July 6, 2021.
He served as a director since September 2020 and was on Audit, Finance and Investment, and Science and Technology committees.
Resignation due to his new role as CEO of Vifor Pharma Group, not due to any disagreements with Teva.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Abbas Hussain

Director

TEVA · TEVA PHARMACEUTICAL INDUSTRIES LTD

Effective: 2021-07-06
Filed: July 6, 2021, 7:59 PM ET

On July 2, 2021, Abbas Hussain informed Teva Pharmaceutical Industries Limited (“Teva”) that, in light of his new role and increased responsibilities as Chief Executive Officer of Vifor Pharma Group, he would resign from Teva’s Board of Directors, effective as of July 6, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Abbas Hussain resigned as Director at TEVA PHARMACEUTICAL INDUSTRIES LTD.

Action: resigned
Role: Director

Exact text from the filing

On July 2, 2021, Abbas Hussain informed Teva Pharmaceutical Industries Limited (“Teva”) that, in light of his new role and increased responsibilities as Chief Executive Officer of Vifor Pharma Group, he would resign from Teva’s Board of Directors, effective as of July 6, 2021.

View on SEC.gov

TEVA PHARMACEUTICAL INDUSTRIES LTD filing history →

Source: SEC EDGAR

accession 0001193125-21-208710

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.